Uh we're starting with news that just crossed a few moments ago. Novo Nordis expanding legal action to protect patents from unsafe non-FDA approved semiglutide. And joining us now is CNBC health and pharmaceuticals reporter Angelica Peebles and CNBC's Brandon Gomez.Uh let's start right here. And Brandon, I'm going to kick this off with you. You're on set with me because we did see him and hers.They reported earnings after the bell last night. It was ugly. They clawed back to the flatline and now they're dow ...

Market Opportunity - A $450 licensing fee oversight by Novo Nordisk opened a billion-dollar weight loss market opportunity in Canada [1] - Hims and Hers plans to expand to Canada in 2026, offering a generic semaglutide drug [3] - The semaglutide market in Canada generated $1.18 billion in revenue in 2024 and is estimated to reach $4 billion in the next decade [3] Patent and Regulatory Landscape - Novo Nordisk will lose its exclusive patent on semaglutide in Canada next January due to a missed licensing fee payment [1] - The patent could have lasted until 2032 if Novo Nordisk had maintained the annual fee payments [2] - The last fee payment was made in 2018, and Novo Nordisk received a notification in 2019 with a one-year deadline to pay [2] - Hims and Hers is working with an approved partner to comply with local laws and regulations in Canada [4] Company Statements - Novo Nordisk refutes the characterization of the patent lapse as a mistake, stating exclusivity ends as part of a drug's normal life cycle [4] - Hims and Hers expects to launch a semaglutide drug in Canada in 2026, though confirmation is pending [4]